Drug name | Cosentyx® |
INN | Secukinumab |
API type | Secukinumab is a recombinant fully human monoclonal antibody selective for interleukin-17A. Secukinumab is of the IgG1/κ-class produced in Chinese Hamster Ovary (CHO) cells
|
Pharmacotherapeutic group
| Immunosuppressants, interleukin inhibitors
|
ATC code
| L04AC10 |
Target of antibody
| IL 17A; Synonyms: CTLA8, IL-17, IL-17A, IL17, Ctla-8, Ctla8, Il17, ChIL-17, IL-17F, IL17A, CTLA-8
|
General function | |
Short description | |
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
| Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). Secukinumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor, which is expressed on various cell types including keratinocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases. Clinically relevant levels of secukinumab reach the skin and reduce local inflammatory markers. As a direct consequence treatment with secukinumab reduces erythema, induration and desquamation present in plaque psoriasis lesions. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. IL-17A plays a key role in the pathogenesis of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis and is up-regulated in lesional skin in contrast to non-lesional skin of plaque psoriasis patients and in synovial tissue of psoriatic arthritis patients. The frequency of IL-17-producing cells was also significantly higher in the subchondral bone marrow of facet joints from patients with ankylosing spondylitis. |
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Serum levels of total IL-17A (free and secukinumab-bound IL-17A) are initially increased in patients receiving secukinumab. This is followed by a slow decrease due to reduced clearance of secukinumab-bound IL-17A, indicating that secukinumab selectively captures free IL-17A, which plays a key role in the pathogenesis of plaque psoriasis.
In a study with secukinumab, infiltrating epidermal neutrophils and various neutrophil-associated markers that are increased in lesional skin of plaque psoriasis patients were significantly reduced after one to two weeks of treatment.
Secukinumab has been shown to lower (within 1 to 2 weeks of treatment) levels of C-reactive protein, which is a marker of inflammation. |
Original license holder
| |
Marketing authorisation numbers
| EU/1/14/980/001 - 007
|
Marketing authorisation holder
| Novartis Europharm Limited
Frimley Business Park
Camberley GU16 7SR
United Kingdom |
Name of the manufacturer of the biological active substance
| |
Name and address of the manufacturer(s) responsible for batch release | Roche Pharma AG
Emil-Barrell-Str. 1,
D-79639 Grenzach-Wyhlen
Germany |
Max shelf life
| 36 months
|
Storage conditions
| 2°C – 8°C
|
List of excipients
| Sucrose
L-histidine
L-histidine hydrochloride-monohydrate
Polysorbate 80 |
| |
| |